Does the concurrent use of anthracycline and granulocyte colony-stimulating factor influence the risk of secondary leukaemia in breast cancer women? [3]

Annals of Oncology

Volumn 16, Issue 7, 2005, Pages 1209-1210

  Di Cosimo, S ^a   Ferretti, G ^a   Papaldo, P ^a   Carlini, P ^a   Fabi, A ^a   Ruggeri, E M ^a   Alimonti, A ^a   Nardoni, C ^a   Cognetti, F ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; CYCLOPHOSPHAMIDE; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GYRASE INHIBITOR; LONIDAMINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HUMAN; LETTER; MONOCYTIC LEUKEMIA; MYELODYSPLASIA; PRIORITY JOURNAL; SECOND CANCER; ACUTE DISEASE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; MIDDLE AGED; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ACUTE DISEASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKEMIA, MYELOID; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; RISK FACTORS;

EID: 25444485144     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi201     Document Type: Letter

References (6)

1. Shapiro CL, Rech A. Side effects of adjuvant treatment of breast cancer. N Engl J Med 2001; 344: 1997-2008.
2. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med 1992; 327: 99-106.
3. Crump M, Tu D, Shepherd L et al. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: A report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21: 3066-3071.
4. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21: 1431-1439.
5. Smith RE, Bryant J, DeCillis A, Anderson S. National Surgical Adjuvant Breast and Bowel Project Experience. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: The National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 2003; 21: 1195-1204.
6. Papaldo P, Lopes M, Cortesi E et al. The addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high dose epirubicin and cyclophosphamide. J Clin Oncol 2003; 21: 3462-3468.